Begin Main Content Area

​Pharmacy and Therapeutics (P&T) Committee

Related Links

The Department of Human Services (Department) appointed the P&T Committee to act in an advisory capacity to the Department and the Office of Medical Assistance Programs (OMAP) and provide an unbiased clinical perspective on the Department's Statewide Preferred Drug List (PDL). Recommendations from the committee must be reviewed and approved by the Secretary of the Department of Human Services.

Change Healthcare provides clinical and financial analysis support to the P&T Committee.

P&T Committee Meeting Information 

Upcoming Meetings

Tuesday, September 13, 2022, 12:00pm-4:00pm EDT and Wednesday, September 14, 2022, 9:00am-4:00pm EDT

The September P&T Committee meetings will be held virtually.

Register for the Webinars:

Register for DHS Pharmacy & Therapeutics Committee on September 14, 2022, 9:00 AM EDT at:

Register for DHS Pharmacy & Therapeutics Committee on September 13, 2022, 12:00 PM EDT at:

Public Testimony:

All members of the public may register to provide verbal or written testimony related to a drug or class of drugs included on the Statewide PDL at the P&T Committee meetings.

Regisration for testimony must be received by Tuesday, August 30, 2022. To register, please go to:

Written testimony will be accepted and must be submitted by Tuesday, August, 30, 2022. The written testimony will be distributed to all P&T Committee members prior to the meetings. Testimony should be emailed to 

The drug classes for review will be posted prior to the meeting.

Past Pharmacy and Therapeutics Committee Meetings
Review the Pharmacy and Therapeutics Committee By-Laws

Committee Information

Composition and responsibilities of the committee:

    • Comprised of department medical directors, external physicians, pharmacists, consumer advocates, and specialists as needed for drug class reviews.
    • Recommend a clinically-based PDL with an emphasis on effectiveness, safety, and outcomes.
    • Recommend prior authorization guidelines for non-preferred drugs as well as certain preferred drugs using current community standards for prescribing.
    • Recommend Prospective and Retrospective Drug Utilization Review Program Review and Development.
Name Specialty  Independent*  Department**  MCO
Ivonne Acrich, MDAd Hoc Child/Adolescent Psychiatrist
​Dale Adair, MD, FAPA​Office of Mental Health & Substance Abuse Services Medical Director​X
Christopher Antypas, PharmDCommunity PharmacistX  
Lawrence Appel, MD, SFHMMedical Director, Office of Long Term Living
Cheston Berlin, Jr., MDPediatricianX
​Tony Byler, MD​PerformCare Psychiatrist​X

Terri Cathers, PharmD,
Chair (tie-breaker vote only)

OMAP Pharmacy Director
Sharon Connor, PharmDAcademic PharmacistX  
​Oluwatoyin Fadeyibi, PharmD, MPH​Community Behavioral Health Pharmacist​X
Andrea Fox, MDInternistX  
Donald Gerhart, RPhCommunity PharmacistX  
James Hancovsky, RPh, MBAUnited Health Care Pharmacy Director  X
David Haverstick, MDFamily PractitionerX  
Rosemary Keffer, MDAd Hoc Adult Psychiatrist X 
​David Kelley, MD​OMAP Chief Medical Officer, Office of Medical Assistance Programs​X
Peter Kreckel, RPhCommunity PharmacistX  
Renee Licwinko, RPhGateway Health Plan Pharmacist  X
​Hannah Livengood, PharmD​Health Partners of Philadelphia Pharmacist​X
Andrew Maiorini, PharmDKeystone/AmeriHealth Perform Rx Clinical Pharmacist  X
Meghan McNelly, PharmDPA Health & Wellness Pharmacist  X
Michele Musheno, RPh, MSAcademic/Hospital PharmacistX  
​Geoffrey Neimark, MD​Community Care Behavioral Health Psychiatrist​X
Natalie Nkurunziza, PharmDAetna Better Health Pharmacist  X
​Louis Parrott Jr., MD, PhD​Magellan Healthcare Psychiatrist​X
Ian Paul, MDPediatricianX  
Adam Raphael Rom, MDFamily PractitionerX  
Amy Saracino, MDAd Hoc Adult Psychiatrist X 
Kevin Szczecina, RPhGeisinger Health Plan Pharmacist  X
​Mahmood Usman, MD​Beacon Health Options Psychiatrist​X
Andreas Wali, MDCardiologistX  
Lloyd WertzConsumer/Family AdvocateX  
​Lauren Zandier, PharmD​UPMC For You Pharmacist​X
VacantConsumer RepresentativeX  

 * - Independent Members are not employed by the Department
** - Department Members are employed by the Department on a full or part-time basis

Effective October 22, 2020 / Last modified March 14, 2022